Head-to-Head

Eli Lilly & Co. vs. Lexicon Pharmaceuticals, Inc.

LLY

Eli Lilly & Co.

$1231.94 +3.90%

VS LXRX

Lexicon Pharmaceuticals, Inc.

$2.40 -2.83%

Eli Lilly & Co. (LLY) comes out ahead, leading on 7 of 8 compared factors.

Size & Scale

LLYLXRX
Market Cap $1.10 trillion $1.07 billion
Revenue (TTM) $79.67 billion $41.47 million
Net Income (TTM) $26.71 billion $-61,117,000

LLY leads on 3 of 3 size & scale factors.

Valuation

LLYLXRX
P/E Ratio 41.35 —
Price / Book 32.41 6.12
Price / Sales 13.78 25.75

LLY and LXRX split the valuation factors evenly.

Profitability

LLYLXRX
Net Margin 33.53% -147.38%
Return on Equity 78.84% -35.02%

LLY leads on 2 of 2 profitability factors.

Dividend

LLYLXRX
Dividend Yield 0.56% —
Payout Ratio 23.23 —

LLY and LXRX split the dividend factors evenly.

Risk & Sentiment

LLYLXRX
Short Interest 1.29% 2.42%

LLY leads on 1 of 1 risk & sentiment factors.

Dig deeper: LLY overview, LLY financials, LXRX overview, LXRX financials.

Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.